Carbamylated haemoglobin arises from the non-enzymic modification of haemoglobin monomers by isocyanate derived from the spontaneous dissociation of urea. We measured carbamylated haemoglobin by high performance liquid chromatography in healthy subjects, non-uraemic hospital patients, diabetics, and different groups of uraemic patients. Carbamylated haemoglobin levels were found to be raised in uraemic subjects, but were independent of age, sex, glycaemic state and haemodialysis procedure. There was no significant difference in carbamylated haemoglobin levels between two groups of patients having different modes of dialysis treatment, probably indicating a similar degree of uraemic exposure in these patients.
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also found that carbamylated haemoglobin coeluted with glycated haemoglobin (HbA 1 ) in ionexchange chromatography giving rise to spuriously high levels of HbA I in uraemic patients without diabetes.
In this study, using a newly developed in-house high performance liquid chromatography (HPLC) method," we measured carbamylated haemoglobin levels in healthy subjects, hospital in-patients with normal renal function, diabetic patients and different groups of uraemic patients, with the aim of evaluating the use of this index in uraemia.
PATIENTS AND METHODS
A total of 196 subjects divided into seven groups were studied. The groups were (I) 30 healthy medical, nursing and laboratory personnel (HC); (II) 33 unselected hospital in-patients with normal renal function (IC); (1lI) 29 out-patient diabetics with normal renal function including both insulin and non-insulin dependent diabetics (DM); (IV) 43 renal out-patients with stable chronic renal failure of a wide spectrum of renal diseases (CRF); (V) 18 uraemic patients on continous ambulatory peritoneal dialysis (CAPD); (VI) 27 uraemic haemodialysis patients (HD); and (VII) 16 successfully transplanted renal patients (TX). None of the subjects had received a blood transfusion within 8 weeks of the study. All the dialysis patients studied had been on dialysis for more than 2 months. Patients with stable chronic renal failure (Group IV) were selected because their renal function had been stable for at least 2 months prior to the study, and none of these patients had required dialysis. None of the uraemic patients suffered from diabetes mellitus. (In our previous communication,' the levels of carbamylated haemoglobin were reported in 25 healthy subjects from Group I, 24 diabetics from Group II and 30 subjects with chronic renal failure from Group IV.)
A subsidiary study was carried out to determine whether haemodialysis altered carbamylated haemoglobin levels. Carbamylated haemoglobin levels were determined pre-and post-dialysis in 15 haemodialysis patients.
Venous blood samples (pre-dialysis in the haemodialysis patients and random morning samples in the others) were collected and divided into aliquots for the measurement of haemoglobin, plasma urea, plasma creatinine and carbamylated haemoglobin. Measurements 'of urea and creatinine were carried out using standard procedures on an Astra 8 analyser (Beckman Instruments, High Wycombe, UK) and haemoglobin measurements on a H6000 Cell Counter (Technicon Instruments, Basingstoke, UK). The HPLC method for measuring carbamylated haemoglobin was as described previously. S Carbamylated haemoglobin was expressed as microgram carbamyl valine per gram haemoglobin <J.tgCV Ig Hb). The within-run and between-run coefficients of variation for carbamylated haemoglobin measurements were both below 8070.
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Statistical methods
The Mann-Whitney U test was used for data comparison between groups, and linear regression analysis was used for data correlation. The paired t-test was used for data comparison for the paired pre-and post-haernodialysis carbamylated haemoglobin levels in the haemodialysis patients.
RESULTS
The results from our subjects are summarized in Table I . There was no significant difference in the carbamylated haemoglobin concentrations between the two non-uraemic control groups (Groups I and II) or between the controls and the non-uraemic diabetics (Group III). There was a wide range of renal function seen in the CRF patients (plasma urea, 8'4-48'3 mmollL; plasma creatinine, 195-1193 /LmoIlL) with a corresponding 10 fold range of carbamylated haemoglobin levels (41-420 /LgCVIgHb). Significantly elevated carbamylated haemoglobin levels were seen in all groups of uraemic patients (Group IV to VI) (P<O'OOI) as compared with the controls and the non-uraemic diabetics, whereas intermediate levels were seen in the successfully transplanted patients (Group VII) commensurate with their plasma urea levels. No significant sex difference in carbamylated haemoglobin levels was found in the two controls and the diabetic groups. No difference in carbamylated haemoglobin levels was also detected with age when the carbamylated haemoglobin results of these three non-uraemic groups were pooled together and divided into three age-groups:
(I) age < 25 years (n = 18); (II) 26-50 years (n = 47) and (III) > 50 years (n = 27). 
DISCUSSION
Carbamylated haemoglobin has been shown to interfere with methods for measuring glycated haemoglobin which are based on charge separation but not with specific methods, e.g, the specific thiobarbituric acid (TBA) colorimetric methodv" and the specific phenylboronic gel affinity chromatographic method," based on quantifying the covalently linked sugar. This could explain the apparent elevated levels of HbA I found in uraemic patients.v"? It is therefore prudent to exercise caution in interpreting glycated haemoglobin results in patients with renal failure, with or without diabetes . In this study, as in our previous study, similar levels of carbamylated haemoglobin were found in both the controls and the non-uraemic diabetics showing that glycosylation does not interfere with our carbamylated haemoglobin assay. The strongly significant correlation between plasma urea and carbamylated haemoglobin levels in patients with successful renal transplants, in patients with stable chronic renal failure and in patients undergoing continuous ambulatory peritoneal dialysis (CAPD), whose plasma urea levels tend to be fairly constant, demonstrates that carbamylated haemoglobin is an urea derived haemoglobin adduct.
Due to the large fluctuation in urea concentrations between dialyses in the haemodialysis patients, the correlation between carbamylated haemoglobin and pre-dialysis urea was weaker than that of the other groups. No significant difference was, however, recorded in the carbamylated haemoglobin levels between the haemodialysis and CAPD patients. This lack of difference probably indicated a similar degree of uraemic exposure experienced by these two groups of dialysis patients.
Carbamylated haemoglobin may provide a better index of chronic uraemic exposure than a single measurement of urea which is subjected to day-to-day dietary and metabolic influences. However, carbamylated haemoglobin levels are affected by factors influencing the half-life of erythrocytes such as haemolytic anaemia and blood transfusion. This may limit its use in uraemic patients who require frequent transfusion, although the increasing use of erythropoietin in the treatment of uraemic anaemia has reduced the requirement for this.
It is conceivable that carbamylated haemoglobin could be used as a marker to determine the time for commencement of dialysis, to assess the rate of progression of renal failure, to monitor the dietary compliance in conservatively treated uraemic patients, to assess the adequacy of dialysis and to guide therapy to minimize uraemic complications. However, further clinical studies will be required. There was also no significant difference between the pre-and post-dialysis carbamylated haemoglobin levels in the haemodialysis patients [n = 15; means(SD): 136(38) versus 133(42) /LgCV/gHb] showing that the haemodialysis procedure did not affect their carbarnylated haemoglobin levels. Figure 1 shows the significant correlation between carbamylated haemoglobin and plasma urea in the uraemic patients. Much poorer correlation was, however, seen between carbamylated haemoglobin and plasma creatinine in the same groups (data not shown). 
